Grant Income	12 Months Ended
Dec. 31, 2022
Grant Income
Grant Income	(4) Grant Income In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $36,754 for the years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 during the year ended December 31, 2021 and recorded a grant receivable of $0 as of December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were no remaining funds available under the grant.

Grant Income

12 Months Ended

Dec. 31, 2022

(4) Grant Income

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $36,754 for the years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 during the year ended December 31, 2021 and recorded a grant receivable of $0 as of December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were no remaining funds available under the grant.